References
- Bollen P, Reiss P, Schapiro J, Burger D. (2015). Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection. Expert Opin Drug Saf 14:1457–72
- Brouwer KL, Keppler D, International Transporter Consortium, et al. (2013). In vitro methods to support transporter evaluation in drug discovery and development. Clin Pharmacol Ther 94:95–112
- Campbell SD, De Morais SM, Xu JJ. (2004). Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150:179–87
- Chiou WJ, De Morais SM, Kikuchi R, et al. (2014). In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica 44:276–82
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
- EMA. (2012). Guideline on the investigation of drug interactions. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
- FDA. (2012). Guidance for industry. Drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations: draft guidance. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
- Fichtenbaum CJ, Gerber JG, Rosenkranz SL, NIAID AIDS Clinical Trials Group, et al. (2002). Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 16:569–77
- Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
- Giorgi EP, Crosignani PG. (1969). Competitive binding of free and conjugated oestrogens to plasma proteins. J Endocrinol 44:219–30
- Glaxosmithkline, Tivicay (dolutegravir) prescribing information. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF [last accessed 7 July 2015]
- Jacobson JM, Davidian M, Rainey PM, et al. (1996). Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for toxoplasma gondii. Antimicrob Agents Chemother 40:1360–5
- Kikuchi R, Lao Y, Bow DA, et al. (2013). Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). J Pharm Sci 102:4426–32
- Letschert K, Keppler D, Konig J. (2004). Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14:441–52
- Morrissey KM, Stocker SL, Wittwer MB, et al. (2013). Renal transporters in drug development. Annu Rev Pharmacol Toxicol 53:503–29
- PMDA. (2014). Drug Interaction Guideline for Drug Development and Provision of Appropriate Information (draft). In Japanese. Available from: http://www.nihs.go.jp/mhlw/20131488.pdf
- Prueksaritanont T, Chu X, Evers R, et al. (2014). Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol 78:587–98
- Reese MJ, Savina PM, Generaux GT, et al. (2013). In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 41:353–61
- Riccardi K, Cawley S, Yates PD, et al. (2015). Plasma protein binding of challenging compounds. J Pharm Sci 104:2627–36
- Rosenthal HE, Pietrzak E, Slaunwhite WR, Jr. Sandberg AA. (1972). Binding of estrone sulfate in human plasma. J Clin Endocrinol Metab 34:805–13
- Shibukawa A, Sawada T, Nakao C, et al. (1995). High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma. J Chromatogr A 697:337–43
- Smith NF, Marsh S, Scott-Horton TJ, et al. (2007). Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 81:76–82
- Song I, Min SS, Borland J, et al. (2010). Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr 55:365–7
- Takeda M, Khamdang S, Narikawa S, et al. (2002). Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 302:666–71
- Tweedie D, Polli JW, International Transporter Consortium, et al. (2013). Transporter studies in drug development: experience to date and follow-up on decision trees from the international transporter consortium. Clin Pharmacol Ther 94:113–25
- Van De Steeg E, Greupink R, Schreurs M, et al. (2013). Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1. Drug Metab Dispos 41:592–601
- Yoshida K, Maeda K, Sugiyama Y. (2012). Transporter-mediated drug–drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther 91:1053–64
- Zong J, Borland J, Jerva F, et al. (2014). The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Int AIDS Soc 17:19584